Naramig (Naratriptan)

Naratriptan, the active ingredient in Naramig, is a Triptan presented as an oral tablet for oral use. It is used for the acute treatment of migraine attacks in adults. GNH USA supplies Naramig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan belongs to the Triptan class and is indicated for acute migraine management. - Migraine (with aura): provides rapid relief of headache pain and associated symptoms. - Migraine (without aura): reduces severity and duration of migraine attacks. - Acute migraine attack: offers prompt alleviation of headache when taken at onset.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient feeling of light‑headedness. - Fatigue: unusual tiredness after dosing. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Chest pain: possible cardiac discomfort requiring immediate evaluation. - Serotonin syndrome: rare but severe condition when combined with serotonergic agents. - Severe hypertension: unexpected rise in blood pressure.

Before prescribing Naramig, consider the following precautions. - Assess cardiovascular risk: evaluate history of coronary artery disease or ischemic heart disease. - Avoid in uncontrolled hypertension: contraindicated in patients with severe high blood pressure. - Caution with other triptans: do not combine with other acute migraine agents of the same class. - Monitor for serotonin syndrome: especially when patients use SSRIs, SNRIs, or MAO inhibitors. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Naratriptan may interact with several medication classes. Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - Ergotamine derivatives: additive vasoconstriction may cause coronary spasm. - Other triptans: combined use can lead to excessive vasoconstriction. Moderate Interactions (Monitor Closely): - SSRIs/SNRIs: potential for serotonin syndrome, monitor symptoms. - Antihypertensives: may enhance blood‑pressure‑lowering effects. - CYP1A2 inhibitors: can raise naratriptan plasma concentrations, adjust therapy if needed.